0001213900-23-098875.txt : 20231227 0001213900-23-098875.hdr.sgml : 20231227 20231227161523 ACCESSION NUMBER: 0001213900-23-098875 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20231227 DATE AS OF CHANGE: 20231227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 180 Life Sciences Corp. CENTRAL INDEX KEY: 0001690080 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813832378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38105 FILM NUMBER: 231518101 BUSINESS ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-507-0669 MAIL ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: KBL MERGER CORP. IV DATE OF NAME CHANGE: 20161115 DEFA14A 1 ea190767-defa14a_180life.htm DEFINITIVE ADDITIONAL MATERIALS

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

 

Filed by the Registrant
Filed by party other than the registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive additional materials

 

Soliciting material under Rule 14a-12

 

180 LIFE SCIENCES CORP.

(Name of Registrant as Specified in Charter)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

  CONTROL ID:  
180 LIFE SCIENCES CORP. REQUEST ID:  

 

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
for a Special Meeting of Stockholders

  DATE: Friday, February 16, 2024
  TIME: 9:00 A.M. pacific time
  LOCATION: https://agm.issuerdirect.com/atnf
     
HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

PHONE:

Call toll free
1-866-752-8683

FAX:

Send this card to
202-521-3464

INTERNET:
https://www.iproxydirect.com/atnf
and follow the on-screen instructions.

EMAIL:

proxy@iproxydirect.com
Include your Control ID in your email.

 
This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/ATNF  
 
If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before February 2, 2024.
 

you may enter your voting instructions at https://www.iproxydirect.com/ATNF

until 11:59 pm Pacific Time February 15, 2024.

 
The purposes of this meeting are as follows: 

1.    To approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of the Company’s common stock, par value $0.0001 per share, by a ratio of between one-for-four and one-for-forty, inclusive, with the exact ratio to be set at a whole number to be determined by the Company’s board of directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to February 16, 2025 (the “Reverse Split Proposal”);

 

2.    To approve the adoption of the Second Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan;

 

3.    to approve the issuance of more than 19.99% of the Company’s outstanding common stock upon the exercise of certain warrants (the “Nasdaq Proposal”); and

 

4.    to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Reverse Split Proposal or Nasdaq Proposal.

 

Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Special Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.

 

The board of directors has fixed the close of business on December 18, 2023, as the record date for the determination of stockholders entitled to receive notice of the Special Meeting and to vote the shares of our common stock and preferred stock, they held on that date at the meeting or any postponement or adjournment of the meeting.

 

The Board of Directors recommends that you vote ‘for’ all proposals above.
 
Please note - This is not a Proxy Card - you cannot vote by returning this card
           

 

 

 

 

 

 

 

180 Life Sciences Corp.

SHAREHOLDER SERVICES

1 Glenwood Avenue Suite 1001

Raleigh NC 27603

FIRST-CLASS MAIL

US POSTAGE

PAID

RALEIGH NC

PERMIT # 870

 

 

 

Time Sensitive shareholder information enclosed

 

 

 

IMPORTANT SHAREHOLDER INFORMATION

 

your vote is important

 

 

 

 

 

 

 

 

 

 

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^L76_$<6 MBW5E:_8+Z^N;L2-'%9QJQPFW<3N8#^(5A:I+KE[XGUFVL-3OXX[&TM9(K2R6 MW#2M(9-WS2J0/N#N*6V\)ZKJ#V6J7GB+6[2^@214BD6T9H@Y&X$I&5.=JGO0 M!H?\)=^"[[4! +KQ=J\@@F2>/]U;#;(IRIXBYH ZZBN'\ M1Z;KFC>&M4U.#QAJCRVEK).BO!;;254D XBZ<5VL+%X8V;J5!- '.:7_ ,E$ M\1?]>5C_ #GKHY)8X@#)(J9Z;FQ7)W"ZWI7C+4]0L]"DU&UO+6VC5X[F*,JT M9DR"'(_OBLN^63Q'XXT&U\0>&5@MTMKMTCNY(KA9&_=<@*3@CW]: .]^UVW_ M #\P_P#?8I5N8'8*L\;,>@#@UC?\(1X4_P"A:TC_ , H_P#"N<\7^']'T2#1 M[[2/#UBE['JUMY8MH8XG?YONAL#&?>@#H?'7_(@>(/\ L'S_ /H!K>)M9\.:GI\MI(%=[^#"EE(R<-TYKM8@4A13U"@&@!]< MGXEEN+#Q3H.IIIM]>V\$-U')]CA\QD+^7MR,]/E-=910!S'_ F@_P"A;\1_ J^"\_XUEZOJ]QK]QHUK;:!K4)CU.WG>2YM/+1$5LDDYKNZ* "BBB@#__9 end GRAPHIC 4 image_003.jpg GRAPHIC begin 644 image_003.jpg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image_004.jpg GRAPHIC begin 644 image_004.jpg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end